NDAORALTABLET
Approved
Aug 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
DURICEF (cefadroxil/cefadroxil hemihydrate) by AbbVie is clinical pharmacology cefadroxil is rapidly absorbed after oral administration. First approved in 1980.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURICEF (cefadroxil) is a first-generation oral cephalosporin antibiotic that inhibits bacterial cell-wall synthesis, making it bactericidal. It is indicated for infections caused by susceptible gram-positive cocci and some gram-negative organisms. Patients with community-acquired infections such as UTIs, skin infections, and respiratory tract infections are typical users.
LOE Approaching
As a mature antibiotic approaching loss of exclusivity with moderate competitive pressure (30%), this product likely has a stable but small commercial team focused on defending market share in primary care and urgent care channels.
Mechanism of Action
CLINICAL PHARMACOLOGY Cefadroxil is rapidly absorbed after oral administration. Following single doses of 500 mg and 1000 mg, average peak serum concentrations were approximately 16 and 28 mcg/mL, respectively. Measurable levels were present 12 hours after administration. Over 90% of the drug is…
Indications
Worked on DURICEF at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.